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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYBy impairing histone demethylation and locking cells into a reprogramming-prone state, oncometabolites can partially mimic the pro-
cess of induced pluripotent stem cell generation. Using a systems biology approach, combining mathematical modeling, computation,
and proof-of-concept studies with live cells, we found that an oncometabolite-driven pathological version of nuclear reprogramming
increases the speed and efficiency of dedifferentiating committed epithelial cells into stem-like states with only a minimal core of
stemness transcription factors. Our biomathematical model, which introduces nucleosome modification and epigenetic regulation
of cell differentiation genes to account for the direct effects of oncometabolites on nuclear reprogramming, demonstrates that onco-
metabolites markedly lower the ‘‘energy barriers’’ separating non-stem and stem cell attractors, diminishes the average time of nuclear
reprogramming, and increases the size of the basin of attraction of the macrostate occupied by stem cells. These findings establish the
concept of oncometabolic nuclear reprogramming of stemness as a bona fide metabolo-epigenetic mechanism for generation of cancer
stem-like cells.INTRODUCTION
The correct functioning of the epigenome ensures fidelity
in the establishment of gene-expression programs that
are compatible with specific cell identities. The need
for tightly controlled epigenetic landscapes is of critical
importance for stem cells, which are able to both
self-renew and generate differentiated progeny (Barrero
et al., 2010; Chen and Dent, 2014; Papp and Plath,
2013; Spivakov and Fisher, 2007). The inability to stabi-
lize stem cell states and functions by maintaining epige-
nome integrity, a process in which DNA methylation
plays a major role, can trigger pathological self-renewal
processes that ultimately lead to cancer (Ohnishi et al.,
2014; Suva et al., 2013; Tung and Knoepfler, 2015). Inter-
estingly, remodeling of DNA methylation is a cancer-
initiating event manifesting in the presence of particular
types of cancer-driving metabolites, termed oncometabo-
lites, and in the nuclear reprogramming process of tran-
scription factor-generated induced pluripotent stem cell
(iPSC) derivation.StemThe shared mechanism by which abnormal accumula-
tion of the oncometabolites 2-hydroxyglutarate (2HG),
succinate, and fumarate causes potential transformation
to malignancy is the ability to promote DNA hypermethy-
lation through suppression of histone demethylation,
which, in turn, results in the repression of genes involved
in the epigenetic rewiring of lineage-specific differentiation
and in the promotion of stem cell-like transcriptional sig-
natures (Chowdhury et al., 2011; Killian et al., 2013;
Letouze´ et al., 2013; Lu et al., 2012; Terunuma et al.,
2014; Saha et al., 2014; Xiao et al., 2012; Xu et al., 2011;
Yang et al., 2013). The transient expression of stemness-
associated transcription factors, i.e., OCT4, SOX2, KLF4,
and c-MYC, in vivo generates tumors consisting of undiffer-
entiated dysplastic cells exhibiting global changes in DNA
methylation (Ohnishi et al., 2014), suggesting that the
epigenetic regulatory machinery associated with iPSC deri-
vationmight initiate cancer development in amanner that
does not require mutational changes in the genomic
sequence (Ben-David and Benvenisty, 2011; Ohnishi
et al., 2014; Knoepfler, 2009; Tung and Knoepfler, 2015).Cell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authors 273
Figure 1. Computation Simulation of
Oncometabolic Nuclear Reprogramming
Phenomena
(A–C) A stochastic model of oncometabolic
nuclear reprogramming. (A) Top: Schematic
representation of the minimal gene regula-
tory network considered in our stochastic
model, consisting of a coupled pluripo-
tency module (self-activation of Oct4 and
Sox2) and a differentiation module (mutual
antagonism between LSGs). Arrows denote
activation and blunt-ended lines denote
inhibitory interactions. Bottom: Schematic
representation of the competitive binding
model for activation/repression in the min-
imal gene regulatory network. (B) A reali-
zation path in which our stochastic model
was run under baseline conditions (baseline
HDM activity and lack of induction of
stemness-related transcription factors, i.e.,
hi-values as per values given in Table S7
[Supplemental Appendix E] and r1 = r2 = 0).
Since the system is symmetric with respect
to LSG1 and LSG2, a state where O = 0, S = 0,
and L2 = 0, whereas L1 > 0, is also an
absorbing state. (C) A realization path in
which our stochastic model was run under
induction of stemness-related transcription
factors (parameter values r1 = r2 = 1.85 3
107). At the onset of stemness factor in-
duction, i.e., we let r1 > 0 and r2 > 0, the
absorbing states observed in the simulations
shown in (B) are not absorbing any longer
and, therefore, there is a positive probabil-
ity for the system to go from the differen-
tiated cell state to the stem cell state. Left:
Normal-like metabolism, baseline HDM ac-
tivity; right: 2HG-induced reduction of HDM
activity by 5% with respect to the baseline
scenario.
(D–F) Epigenetic landscapes and re-
programming performance in response to
2HG. (D) 2HG-induced inhibition of HDM
activity affects the depth of the stem cell
attractors by lowering the barriers of the
epigenetic landscape. Figures show the joint
probability of the random variables O + S
(stemness factors) and L1 + L2 (LSGs) for
different values of the relative oncometa-
bolic-induced reduction of HDM activity
with respect to the baseline scenario. To
obtain the epigenetic landscapes for dif-
ferent degrees of 2HG-induced reduction of
HDM activity in shorter computational time,
we considered the following parameter
values: r1 = r2 = 5.55 3 10
7 and wo = ws =
0.2. We have also considered that the expression of the LSGs is induced at certain rates given by the following parameter values rL1 = rL2 =
2.783 107. The landscapes with 4%, 5%, and 6% reduced HDM activity correspond to h2 = 0.96, h2 = 0.95, and h2 = 0.94, respectively. The
(legend continued on next page)
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Because oncometabolites partially mimic the process
of iPSC generation, a metabolically driven pathological
version of nuclear reprogramming might represent an un-
derappreciated epigenetic mechanism of enrichment for
cellular states with increased tumor-initiating capacities
and aberrant self-renewal potential (Goding et al., 2014;
Menendez and Alarco´n, 2014; Menendez et al., 2014b),
often termed cancer stem cells. However, although a role
for oncometabolite-driven changes in the epigenetic land-
scape is mechanistically attractive (Lu and Thompson,
2012; Yun et al., 2012; Johnson et al., 2015), the existence
of bona fide oncometabolic reprogramming of differenti-
ated cells into cancer stem-like states has never been
demonstrated. In an attempt to resolve this issue, we have
used a systems biology approach that combinedmathemat-
ical modeling, computation, and proof-of-concept experi-
mental validation of stochastic predictions in vitro.RESULTS
We initially developed methods and procedures for the
mathematical modeling of oncometabolo-epigenetic regu-
latory networks involved in the acquisition of stemness
(see Supplemental Information). Our stochastic model
considers the interactions between aminimal core of stem-
ness-associated transcription factors (OCT4 and SOX2) and
two generic lineage-specific genes (LSG1 and LSG2) (Shu
et al., 2013) (Figure 1A). The basic effector mechanism of
the coupling between metabolism and the epi-transcrip-
tional reprogramming system relies on histone- and
nucleosome-modifying enzymes (Dodd et al., 2007). In
particular, we considered a metabolo-epigenetic link in
which the oncometabolite 2HG drastically inhibits the
activity of DNA histone demethylases (HDMs), thus re-
stricting the methylation plasticity that is required for the
transition between stem cells and differentiated cells (Lu
and Thompson, 2012; Lu et al., 2012).
The first consistency check we performed was that the
‘‘normal metabolism’’ scenario, defined as baseline HDMremaining parameter values are given in Table S7 (Supplemental Ap
kinetic efficiency of the reprogramming process. The panel shows statis
density, P(TE), as a function of the 2HG-induced reduction of HDM
distribution of TE, P(TE) is approximately exponential. The lower p
programming time, illustrating that the reprogramming rate increases
activity reductions of 0%, 2.5%, 5%, and 7.5% correspond to h2 = 1.00
inhibition of HDM activity affects the size of the basin of attraction
semiclassical QSSA approximation (see Equations 29–32 and 40–44 in
inhibition (h2 = 1.00, red line), and for the case with a 2HG-induced 5
scenario converges to the differentiated cell state (red line), whereas
Parameter values r1 = r2 = 1.853 10
7, cE1 = cE2 = 2, Co = CS = C1 = C2
Table S7 (Supplemental Appendix E).
Stemactivity and lack of induction of stemness transcription fac-
tors, should lead to cell differentiation. Figure 1B shows
that, after an initial transient regime, the system settles
down to a steady state whereby the protein levels of
OCT4, SOX2, and LSG1 decay to zero, whereas LSG2 pro-
tein climbs to its stationary positive value. In the absence
of induction, this cellular state is an absorbing state, i.e.,
once reached by the system it is not possible to exit. Fig-
ure 1C (left panel) shows a particular sample path where
reprogramming of stemness is accomplished by merely
adding OCT4 and SOX2 to the baseline scenario. Impor-
tantly, under baseline conditions both LSG1 and LSG2 are
predominantly acetylated and, therefore, their promoters
remain accessible to transcription factors, with short-lived
journeys into the methylated state (Supplemental Appen-
dix D). Despite the fact that during episodes of transient
methylation the expression levels of the LSGs become
downregulated, this does not necessarily lead to reprog-
ramming since the stochastic dynamics of the gene regula-
tory network has to pass through an unstable saddle
point (Supplemental Appendix E). Therefore, several epi-
sodes of transientmethylation should occur before a period
of transient methylation of sufficient duration allows the
gene-regulation system to successfully pass through the
bottleneck.
We then introduced the ability of 2HG to reduce HDM
activity. Figure 1C (right panel) shows a realization of
the stochastic model whereby reprogramming is achieved
with a 5% reduction of HDM activity with respect to the
baseline scenario (Figure 1C, left panel). Oncometabolic
reduction of HDM activity increases the characteristic
duration of the transient episodes of methylation (Supple-
mental Appendix D) which, in turn, increases the likeli-
hood of one such period of sufficient duration for the
gene regulatory system to overcome the bottleneck. In
this scenario, the system must transit from the differenti-
ated state to the stem cell state. Figure 1D illustrates how
the relative height of the peak corresponding to the stem
cell state increases in relation to the peak corresponding
to the differentiated cell state, thus implying that thependix E). (E) 2HG-induced inhibition of HDM activity affects the
tics of the average reprogramming time, TE, as well as its probability
activity. The top panels illustrate that the predicted probability
anel shows the average and SD (error bars) of the predicted re-
exponentially with the 2HG-induced reduction of HDM activity. HDM
, h2 = 0.975, h2 = 0.95, and h2 = 0.925, respectively. (F) 2HG-induced
of the induced stem cell state. The graphic shows a solution of the
Supplemental Information) for the baseline scenario with no HDM
% reduction in HDM activity (h2 = 0.95, blue line). The uninhibited
the inhibited scenario converges to the stem cell state (blue line).
= 1, and wo = ws = 0.2. The remaining parameter values are given in
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epigenetic barriers are significantly lowered in response to
2HG-induced reduction of HDM activity. There is a ‘‘third
peak’’ that arises from the fact that, while attempting re-
programming, the gene regulatory system spends a long
time in the vicinity of the saddle point, trying to overcome
the bottleneck. The height of this third peak appears to
be rather insensitive to the 2HG-regulated activity of
HDM, as it depends on the kinetic parameters of the gene
regulatory system alone. Figure 1E shows the immediate
and significant consequences for the kinetic efficiency
of nuclear reprogramming; specifically, the reduction in
average reprogramming time varies exponentially with
the 2HG-induced reduction of HDM activity. Therefore,
even modest 2HG-driven reductions of HDM activity are
predicted to drive a considerable increase in the reprogram-
ming efficiency.
We finally interrogated our stochastic model to examine
whether the basins of attractions of each of these cell states,
i.e., the set of developmental states which are attracted to
each of them, are also altered in response to 2HG-induced
reduction of HDM activity. We carried out a semiclassical
quasi-steady-state approximation (QSSA) (Supplemental
Appendix B) to analyze the existence of initial conditions
that, in the absence of HDM inhibition, converge to a
differentiated cell state and, upon inhibition, converge to
the stem cell state. We found that such initial conditions
exist, i.e., a portion of the basin of attraction of the differ-
entiated cell state is transferred to the stem cell state
uponHDM inhibition. Figure 1F illustrates how oncometa-
bolic-induced repression of HDM activity actually enlarges
the basin of attraction of the stem cell state.
Nishi et al. (2014a, 2014b) have developed a method of
inducing cancer stem-like cells (CSCs) through the reprog-
ramming and partial differentiation of the immortalized
but otherwise normal MCF10A human mammary epithe-
lial cell line. To experimentally test our computational
model of oncometabolic nuclear reprogramming, we simi-
larly employed theMCF10A cell line and an isogenic deriv-
ative endogenously heterozygous for the R132H mutation
of isocitrate dehydrogenase 1 (IDH1) gene, generating
2HG (Grassian et al., 2012). Quantification of intracellular
2HG showed that the levels of the oncometabolite were
more than 30-fold higher in cell lysates from the knockin
MCF10A IDH1R132H/WT cells, confirming neomorphic
IDH1R132H enzymatic activity (Figure 2A). To corroborate
that the sole accumulation of 2HG in an otherwise isogenic
background was sufficient to significantly impair histone
demethylation, we examined the pattern of histone lysine
methylation in IDH1R132H/WT knockin and parental cells.
Western blot analysis showed that the global levels of
H3K4me3, H3K9me3, and H3K27me3 were increased in
2HG-overproducing MCF10A knockin cells compared
with IDH1WT/WT parental cells (Figure 2A). These results276 Stem Cell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authowere consistent with 2HG-induced broad inhibition of his-
tone demethylation, showing agreement with previous
models overexpressing IDH mutants (Duncan et al., 2012;
Lu et al., 2012). We then employed a commercially avail-
able ELISA-based global DNA methylation able to indi-
rectly provide a global measurement of 5-methtylcytosine
(5-mC) levels in genomic DNA obtained from IDH1WT/WT
and IDH1R132H/WT knockin cells. Measurement of 5-mC
levels of long interspersed nucleotide element 1 (LINE-1)
confirmed that LINE-1methylation significantly increased
in 2HG-overproducing IDH1R132H/WT cells when compared
with IDH1WT/WT parental cells. Remarkably, a 2-day treat-
ment with the selective R132H-IDH1 inhibitor AGI-5198,
which fully suppressed 2HG to background levels (Fig-
ure 2A), partially reverted LINE-1 hypermethylation in
IDH1R132H/WT cells.
Because it could be argued that 2HG-induced chromatin
reorganizationmight promote the pluripotency-associated
genes transition from an inactive to an active stage, we
assessed whether the overproduction of 2HG promoted
the expression of pluripotency regulators in normal breast
epithelial cells. Flow cytometry analyses confirmed that the
baseline expression of the core transcription factors OCT4
and SOX2 remained essentially unaltered in IDH1R132H/WT
knockin cells comparedwith parental IDH1WT/WTcells (Fig-
ure 2B). A preliminary evaluation of the top ten most sig-
nificant Gene Ontology (GO) ‘‘molecular function’’ and
‘‘biological process’’ term annotations overrepresented in
the 290 differentially hypermethylated CpG sites that
were identified in IDH1R132H/WT knockin cells (Figure 2C)
strongly suggested that 2HG had a significant impact on
the transcriptional repression of differentiation programs.
Intracellular accumulation of the oncometabolite 2HG
due to the heterozygous expression of the IDH1R132H allele
is therefore sufficient to notably alter global histone lysine
methylation without varying the baseline expression of
the most critical reprogramming factors (i.e., OCT4 and
SOX2) but altering expression of differentiation genes,
thus providing an idoneous experimental model to vali-
date the stochastic predictions of our biomathematical
model in vitro.
MCF10A IDH1R132H/WT and MCF10A IDH1WT/WT cells
were then transduced with OCT4 and SOX2 (hereafter
called OS) to examine whether endogenously produced
2HG could substitute for combinations of stemness factors
(i.e., KLF4 and c-MYC) to reprogram MCF10A mammary
cells into iPS-like (iPSL-10A) cells. At day 15 after infection,
MCF10A IDH1R132H/WT cells growing on feeder layers
showed a >10-fold increase in reprogramming efficiency
relative to MCF10A IDH1WT/WT cells, as assessed by count-
ing the number of alkaline phosphatase (AP)-positive (AP+)
colonies (Figure 3A). We found that the colonies identified
by the highly AP+ criterion were also positive for strongrs
Figure 2. Effects of 2HG on Histone De-
methylation, Activation of Pluripotency
Genes, and Genome-wide DNA Methyl-
ation
(A) Top: Base-peak chromatograms of ex-
tracts from IDH1WT/WT cells (black line),
IDH1R132H/WT cells (red line), and
IDH1R132H/WT cells treated with 40 mmol/l
AGI-5198 for 2 days (blue line). A combined
mass spectrum of the region where 2HG was
eluted (m/z 349.1317) is shown in the inset
(two technical replicates per n; n = 3 bio-
logical replicates). Bottom: 2HG promotes
broad inhibition of histone demethylation
and LINE-1 global methylation. Left panel,
western blots for total H3K4me3, H3K9me3,
and H3K27me3 histone modifications
in parental IDH1WT/WT and IDH1R132H/WT
knockin cells. Also shown are total H3
controls (two technical replicates per n;
n = 2 biological replicates). Middle and
right panels, % of 5-mC relative to either
detectable CpG residues or total cytosine
content in IDH1WT/WT and IDH1R132H/WT
cells, the latter being cultured in the
absence or presence of 40 mmol/l AGI-5198
for 2 days. The data are presented as the
mean ± SD (error bars); three technical
replicates per n; n = 2 biological replicates.
(B and C) 2HG impairs differentiation but
does not elevate the baseline expression of
core pluripotency factors. (B) Flow cy-
tometry analysis of OCT4/SOX2 expression
in IDH1WT/WT and IDH1R132H/WT knockin
cells. Representative dot plots showing the
distribution of IDH1WT/WT and IDH1R132H/WT
cells along the signal obtained with the isotype-specific control antibodies or with the OCT3,4 and SOX2 direct conjugated antibodies (two
technical replicates per n; n = 2 biological replicates). (C) Ten top-ranked GO molecular functions and biological processes associated with
hypermethylated genes in IDH1R132H/WT cells (accession number GEO: GSE76263). x axis, negative logarithm (-lg) of the p value; y axis,
GO category.endogenous expression of NANOG (data not shown),
which was considered a characteristic of bona fide iPSL-
10A cells.
For live-cell imaging, we established a 96-well plate-based
screening assay to assess expression of the pluripotency-
associated surface marker TRA-1-60, a more reliable and
specific marker for predicting successful reprogramming
and iPS cell derivation than other markers including AP
(Mali et al., 2010), during reprogramming. Cell clusters
were scored as null, weak, or strong depending on the
expression of TRA-1-60. Cell clusters positive for TRA-1-
60 were detected in MCF10A IDH1R132H/WT cells 2–3 days
earlier relative to MCF10A IDH1WT/WT cells (Figure 3A).
When the standard reprogramming protocol was followed
with four reprogramming factors, OCT4, SOX2, KLF4, andStemc-MYC (hereafter OSKM), a significantly greater number of
AP+ colonies (300) were observed in OSKM-transduced
IDH1R132H/WT cells compared with IDH1WT/WT parental
cells (140) at day 13. TRA-1-60+ clusters were also
detected at an earlier stage in OSKM-transduced MCF10A
IDH1R132H/WT cells than in MCF10A IDH1WT/WT control
cells (Figure 3A).
Because the stimulatory effect of 2HG on the nuclear re-
programming efficiency was more striking in the absence
of KLF4 and c-MYC transgenes (>10-fold with OS) than in
their presence (2-fold with OSKM), we preliminarily
explored the time frame during which 2HG might exert
its positive reprogramming effects. Exogenous supplemen-
tation of IDH1WT/WT parental cells with 1 mmol/l D-2HG
octylester, a concentration of a cell membrane-permeableCell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authors 277
Figure 3. Effects of 2HG on the Nuclear Reprogramming of Breast Epithelial Cells into CSC-like States
(A) Left panels: Kinetics of reprogramming in the absence or presence of 2HG. MCF10 IDH1WT/WT control cells and 2HG-overproducing
MCF10A IDH1R132H/WT isogenic derivatives were reprogrammed by the retroviral delivery of OS (top) or OSKM (bottom) transcription factors.
Alternatively, octyl-2HG, a cell-permeable esterified form of 2HG, was added at a final concentration of 1 mmol/l to the culture medium
immediately after transduction of IDH1WT/WT parental cells with OS and OSKM, and was maintained for 4 days. The total number of highly
AP+ colonies for each condition was counted at different days until day 15 after transduction under feeder conditions. The data are
presented as the mean ± SD (error bars); n = 3 biological replicates. Representative microphotographs of AP+ colonies are also shown (scale
bar, 5 mm). Middle panels: The reprogramming efficiencies of various conditions were compared with that obtained without octyl-2HG
treatment in IDH1WT/WT parental cells, and are presented as relative fold changes (mean [columns] ± SD [error bars]). Insets show
microscopy images of the representative cell morphology of IDH1WT/WT, IDH1R132H/WT, and IDH1WT/WT cells growing in the presence of octyl-
2HG (scale bar, 10 mm). Right panels: Temporal activation of stemness during reprogramming was analyzed by live-cell staining with an
antibody against TRA-1-60 (n = 3 biological replicates).
(B) Western blots for total H3K4me3, H3K9me3, and H3K27me3 histone modifications in parental IDH1WT/WT and IDH1R132H/WT knockin
cells at day 6 post-OS or post-OSKM transduction. Also shown are total H3 controls (two technical replicates per n; n = 2 biological
replicates). Right panels: Flow cytometry analysis of OCT4/SOX2 expression in CSC-like derivatives obtained from partial differentiation of
reprogrammed IDH1WT/WT and IDH1R132H/WT knockin cells. Representative dot plots showing the distribution of IDH1WT/WT and IDH1R132H/WT
cells along the signal obtained with the isotype-specific control antibodies or with the OCT3,4 and SOX2 direct conjugated antibodies (two
technical replicates per n; n = 2 biological replicates).form of 2HG that has previously been shown to mimic
2HG levels in tumors with aberrant 2HG accumulation
by promoting a >100-fold increased intracellular concen-
tration of 2HG (Lu et al., 2012; Xu et al., 2011; Terunuma
et al., 2014), beginning soon after OS and OSKM transduc-278 Stem Cell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authotion, for 4 days, resulted in a significantly increased num-
ber of reprogrammed colonies (Figure 3A). The fact that
an early short-term supplementation with exogenous
octyl-2HG, which caused prominent epithelial-to-mesen-
chymal (EMT)-like changes in cell fate (Figure 3A), wasrs
sufficient to promote a pro-reprogramming effect similar to
that of continued endogenous exposure in 2HG-overpro-
ducing EMT-like MCF10A IDH1R132H/WT cells (Grassian
et al., 2012), was consistent with the notion that 2HG
might contribute to the time-sensitive activation of a
mesenchymal stage required during the initiation period
of successful reprogramming (Liu et al., 2013; O’Malley
et al., 2013).
Furthermore, increased numbers of AP+ colonies and
TRA-1-60+ clusters were detected within a shorter period
of time in octyl-2HG-treated IDH1WT/WT parental cells (Fig-
ure 3A). Interestingly, when monitoring the effect of 2HG
on the appearance of tightly packed colonies morphologi-
cally resembling human embryonic stem cells (hESCs),
2HG was found to increase the ratio of AP+ iPSL-10A col-
onies to total hESC-like colonies, i.e., the 2HG-driven in-
crease in the number of AP+ iPSL-10A colonies was not
accompanied by changes in the total colony number,
thus implying that 2HG enhances the destination of re-
programmed cells to the stem cell fate (data not shown).
To confirm that the pre-existing status of histonemodifica-
tions might differentially regulate the global chromatin
environment controlling reprogramming toward a plurip-
otent state, we reexamined the global histonemodification
variation that occurred in early stages of reprogramming
(i.e., 6 days after OS and OSKM transduction) before
genuine AP+ iPS-like patches become apparent in the cul-
tures (Figure 3B). Interestingly, H3K9 methylation, which
has been defined as the primary epigenetic determinant
for the intermediate pre-iPS state as its removal leads to
fully reprogrammed iPS cells (Chen et al., 2013), was
notably suppressed by early OS induction in 2HG-overpro-
ducing IDH1R132H/WT cells but not in 2HG-negative
IDH1WT/WT cells. Moreover, a reduction of H3K27me3
and H3K4me3, a phenomenon that has been associated
with the acquisition of a transient open/primed chromatin
state during the early transcriptional events of nuclear re-
programming (Hussein et al., 2014), was apparently
observed upon early OS induction in 2HG-overproducing
IDH1R132H/WT cells but not in 2HG-negative IDH1WT/WT
cells. Thus, whereas the baseline levels of functionally
opposing histone methylation marks were increased in
2HG-overproducing IDH1R132H/WT cells, consistent with a
broad inhibition of histone demethylation, 2HG-induced
histone modifications provided a collaborative rewiring
of the chromatin organization that respondedmore rapidly
and efficiently to the core stemness factors (OS) at the start
of reprogramming.
Because the process of dedifferentiation through the
addition of Yamanaka factors is extremely inefficient, the
actual contribution of de novo generated ‘‘CSC states’’ via
oncometabolic reprogramming to cancer evolution might
be a matter of conjecture. To evaluate such a situation, weStemfirst confirmed that, upon the introduction of defined re-
programming factors and subsequent partial differentia-
tion, proliferating CSC-like cells stably overexpressing
OCT4 and SOX2 with tumor-initiating capacity (Nishi
et al., 2014b) likewise arise from non-CSC, OCT4/SOX2-
negative MCF10A IDH1R132H/WT cells (Figure 3B). We then
designed amathematical model to investigate the expected
dynamics of tumor progressionwhen the presence of onco-
metabolic signals can favor differentiated cells to revert to a
multipotent CSC-like state. When a native, ‘‘resident’’ pop-
ulation sustained by normal stem cells competes with
‘‘invader’’ clones of CSC-like cells generated de novo as
the result of nuclear reprogramming, our mathematical
model predicts that the chances of prolonged survival in-
crease exponentially with the size of the reprogrammed
clones (Supplemental Appendix F). By solely affecting
epigenetic events involving histonemethylation, oncome-
tabolites such as 2HG can functionally replace stemness
transcription factors (e.g., KLF4 and c-MYC) and accelerate
the dedifferentiation rates to efficiently drive the de novo
generation of reprogrammed CSC-like states, thus confirm-
ing that the possibility that metabolically driven nuclear
reprogramming-like phenomena contribute to cancer initi-
ation, and that progression cannot be neglected in terms of
cancer prognosis and therapeutic planning (Brooks et al.,
2015; Leder et al., 2010; Martin-Castillo et al., 2015; Me-
nendez et al., 2014a).
The experimental approach using no-2HG versus 2HG-
overproducing cellular models in an identical non-trans-
formed genomic background, functionally confirms the
predictions of our stochastic model, demonstrating that
an oncometabolite markedly lowers the ‘‘energy barriers’’
separating non-stem and stem cell attractors, diminishes
the average time of reprogramming, and increases the
size of the basin of attraction of the macrostate occupied
by stem cells (Figure 4). For 2HG to improve nuclear reprog-
ramming performance, it is sufficient to be present only
during the first few days of reprogramming, when it ap-
pears to exert partial functional redundancy with other
reprogramming factors that ensure the supply of chro-
matin-modifying enzymes with metabolic intermediates
for the epigenetic activation of stemness-related gene net-
works (Goding et al., 2014; Gut and Verdin, 2013; Menen-
dez and Alarco´n, 2014).DISCUSSION
One of the most challenging issues in the field of cancer
research is understanding how cellular metabolism influ-
ences chromatin structure and the epigenome to drive
tumor formation (Johnson et al., 2015; Menendez and
Alarco´n, 2014; Lu and Thompson, 2012; Yun et al.,Cell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authors 279
Figure 4. Oncometabolite-Driven Nuclear
Reprogramming of Cancer Stemness: A
Framework Proposal
HDMs, such as Jumonji histone demethy-
lases (JHDM) and ten-eleven translocation
(TET) family members, remove repressive
histone methylation marks and activate the
expression of differentiation-related genes
by protecting promoters from aberrant DNA
methylation. Oncometabolites such as 2HG
inhibit the epigenetic ‘‘editors’’ HDMs and
TETs, which leads to histone modifications
(e.g., increased H3K9me3, H3K27me3, and
H3K4me3) and DNA hypermethylation. On-
cometabolites reprogram chromatin state
to promote the downregulation of genes
involved in differentiation as well as bias in
developmental gene-expression patterns.
This metabolo-epigenetic modification of
inactive/poised states of lineage-specific
genes is sufficient to significantly alter the
efficiency and speed of nuclear reprogram-
ming by lowering the ‘‘reprogramming bar-
riers’’ of the epigenetic landscape and
increasing the size of the stem cell state
basin of attraction, which results in the ac-
celeration (i.e., higher efficiency and faster
kinetics) of the nuclear reprogramming
process. Oncometabolites such as 2HG permissively alleviate the unfavorable developmental process of ‘‘jumping’’ from differentiated cell
states to CSC-like attractors while concomitantly stabilizing the ground-state self-maintaining character of CSC states. This conceptual
figure represents cells stabilized in an initial non-CSC attractor and how nuclear reprogramming can make cells exceed the ‘‘reprogramming
barrier,’’ represented as a wall of interlocking bricks, harder or easier in the absence or presence of the oncometabolite 2HG, respectively,
and fall down in a final CSC attractor. The cellular reprogramming process is represented as a dashed line from the initial to the final
cellular state.2012). To date, however, there have been no attempts to
delineate predictive mathematical platforms that opera-
tively integrate the required contribution of certainmetab-
olites for the extensive remodeling of the epigenetic
landscape that drives nuclear reprogramming (Morris
et al., 2014). From a mathematical standpoint, here we
introduce nucleosome modification and epigenetic regu-
lation of lineage-specific genes as an essential element of
stochastic modeling that successfully integrate the recog-
nized ability of oncometabolites to competitively inhibit
epigenetic regulation of cell differentiation with the pro-
cess whereby the stemness regulatory circuitry is estab-
lished during nuclear reprogramming (Ben-David et al.,
2013; Shu et al., 2013). By combining mathematical
modeling and computation simulation with wet-lab
in vitro experiments in an isogenic model, we demon-
strate the existence of bona fide oncometabolic nuclear
reprogramming phenomena able to efficiently generate
CSC-like states (Figure 4). Our model provides a stochastic
tool as well as a conceptual framework that should be
extremely useful in helping to understand and investigate280 Stem Cell Reports j Vol. 6 j 273–283 j March 8, 2016 j ª2016 The Authothe underexplored link between cellular metabolism and
cancer-driving alterations in the epigenome. Beyond the
numerous ‘‘common’’ metabolites that are used as sub-
strates and cofactors for reactions that coordinate epige-
netic status (Locasale, 2013; Johnson et al., 2015; Yun
et al., 2012), a recent systems approach predicted more
than 40 compounds and substructures of potential ‘‘onco-
metabolites’’ that could result from the loss-of-function
and gain-of-function mutations of metabolic enzymes
(Nam et al., 2014). In this context, our model can be a
starting point for future studies on the processes by which
cellular metabolism influences chromatin structure and
epi-transcriptional circuits to causally drive stemness in
cancer tissues.EXPERIMENTAL PROCEDURES
Stochastic Model
A detailed mathematical formulation of the stochastic model of
oncometabolic nuclear reprogramming can be found in the Sup-
plemental Information.rs
Reagents
The octyl ester derivative of [2R]-2-hydroxyglutaric acid was pur-
chased from US Biologicals Life Sciences (cat. #01386; Deltaclon).
AGI-5198, a highly potent and selective inhibitor of IDH1
R132H/R132C mutants, was purchased from Selleck Chemicals
(cat. #S7185).
Cell Lines
MCF10A cells with heterozygous knockin of IDH1 dominant-nega-
tive (R132H) point mutation and MCF10A isogenic parental cells
were obtained from Horizon Discovery (cat. #HD 101-013 and
#HD PAR-058, respectively). IDH1 mutational status was verified
by sequencing (Grassian et al., 2012).
Reprogramming of Human Breast Epithelial Cells and
Cell Infection
MCF10A IDH1R132H/WT and MCF10A IDH1WT/WT cells were trans-
duced with retroviral vectors encoding nuclear reprogramming
factors as previously described (Nishi et al., 2014a, 2014b) (Fig-
ure S1). The pMX vectors containing human cDNA for OCT4,
SOX2, KLF4, and c-MYC were obtained from Addgene (http://
www.addgene.org).
Alkaline Phosphatase Staining
AP staining was performed using the Leukocyte Alkaline Phospha-
tase kit (cat. #86-R; Sigma-Aldrich) according to themanufacturer’s
protocol in OS- and OSKM-transduced cells reseeded onto mouse
embryo fibroblast feeder layers.
Live Staining by the TRA-1-60 Antibody
Amouse anti-human StainAlive TRA-1-60 antibody (DyLight 488;
cat. #09-0068) was employed according to the manufacturer’s pro-
tocol to identify and track the appearance of iPS-like colonies in
OS- and OSKM-transduced cells reseeded onto Matrigel-coated
96-well plates.
Histone Extraction and Western Analysis
Histones were acid-extracted following a modified version of
the original protocol published by Sarg et al. (2002). For western
blot analyses of H3K4me3, H3K9me3, H3K27me3, and total
H3, 12 mg of the histone lysates were electrophoresed on 17%
SDS-PAGE gel, transferred to a 0.45-mm polyvinylidene fluoride
membrane, and incubated with antibodies against histone
H3 (Abcam; cat. #ab1791), H3K4me3 (Abcam; cat. #ab8580),
H3K9me3 (Millipore; cat. #CS200604), and H3K27me3 (Upstate-
Millipore; cat. #07-449, lot #DAM1421462), followed by horse-
radish peroxidase-conjugated secondary and chemiluminescence
detection.
Targeted Metabolomics
Quantitative measurements of 2HG were performed by employ-
ing a method based on gas chromatography coupled to a
quadrupole time-of-flight mass spectrometer and an electron
impact interface (GC-EI-QTOF-MS). A detailed description of
this procedure is given in Cuya`s et al. (2015) and Riera-Borrull
et al. (2016).StemGlobal DNA Methylation
DNA was extracted and purified with a DNeasy Blood & Tissue kit
(Qiagen; cat. #69504 or #69506) according to the manufacturer’s
instructions. Global DNA methylation levels were determined
using the Global DNA Methylation LINE-1 kit (Active Motif;
cat. #55017) according to the manufacturer’s instructions.
Genome-wide DNA Methylation: DNA Methylation
Microarrays and Data Analysis
Microarray-based DNAmethylation profiling was performed using
Illumina Infinium HumanMethylation450 BeadChip Array (Bibi-
kova et al., 2011). Methylation levels (beta values) were obtained
using Illumina’s GenomeStudio Software. The beta value repre-
sents a quantitative measure of the DNA methylation level of spe-
cific CpG sites and ranges from 0 (completely unmethylated) to 1
(completely methylated). Before analyzing the methylation data
(accession number GEO: GSE76263), we excluded possible sources
of technical biases that could alter the results. We excluded probes
with a detection p value of R0.01 and removed the probes con-
taining a SNP at the CpG interrogation site. Because there were
only two samples in the experimental design, we used stringent
statistical criteria to define differential methylated probes. Thus,
we defined a probe to be hypermethylated or hypomethylated if
the differences between beta values was larger than 0.5. The
HOMER (Hypergeometric Optimization of Motif EnRichment)
suite of tools (http://homer.salk.edu/homer/) was used to deter-
mine the enrichment of individual ontology terms and create
GO maps in the groups of differentially methylated genes.
Multivariate Permeabilized Cell Flow Cytometry
OCT3,4 and SOX2 protein levels were analyzed by intracellular
staining using the Fix & Perm Cell Permeabilization kit (Invitro-
gen, cat. #GAS004), and flow cytometry using the anti-hOct4-PE
(Becton Dickinson, cat. #560186) and anti-hSox2-AF488 (BD,
cat. #561593) primary antibodies. Corresponding isotype anti-
bodies MsIgG1 PE (BD, cat. #556650) and MsIgG1 AF488 (BD,
cat. #551954) were used as controls. Plots show the fluorescence
intensity distribution and percentages of cells above or below the
thresholds determined by the stainingwith the isotype antibodies.
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